biowin: the health cluster of wallonia
TRANSCRIPT
BioWin,an open cluster in a challenging global health environment
DAMIEN DALLEMAGNEGeneral Manager
Wallonia, a strong network in health biotechnology
100 biotech/pharma companies , mostly SMEs (turnover of €2,7 billion – 10,000 jobs) + world leaders such as:
125 research units from 3 universities19,000 students in biomed
sciences5,000 PhDs in biomed sciences
Several prestigious research centers (Ludwig Institute, GIGA, Institute for Medical Immunology, ….)
15 higher education schools and training centres
7 university hospitals,1 business network dedicated to clinical research (ARESA), several biotech incubators, a European platform for biologistics, …
Biotech in Wallonia: main fields of activity
Focused on human health => Red biotech = 80% of biotech in Wallonia=> Medical Technologies
Pharmacy/ BiopharmacyDiagnosticsMedical ImagingCell TherapyMedical imagingMedical devicesMedical equipmentsSupport services to industry
R & DPreclinical
Clinical Research
ProductDevel’t.
RegulatoryMarketing
Sales Production Biologistics
From bench to market!
Biopharma, pharma
Diagnostics
Med. devices/equip’t.
Biotech products
Bio-informatics
Technology
Support Services (CRO, CMO, etc.)
Health biotechnology in Wallonia : 3 major hubs
Gosselies
• Stimulate the regional economy
• Increase international attractiveness
• Stimulate job creation
BioWin: 3 strategic missions as a cluster
BioWin’s strategy: 5 axis of developement
Vision 2015
Innovative research projects within three targeted thematics (cancer, inflammation, brain diseases)
1
Training initiatives in order to guaranty the supply of human ressources of excellence
2
Communication actions in order to promote Walloon excellence and raise international visibilty
3
Networking support in order to promote exchanges and collaborations between partners
4
Attracting public and private funding in order to support the long term development of the cluster
5
Three major drivers of development
• Excellence of research
• Outstanding human capital
• International attractiveness
+ special focus on the needs of SMEs !
Excellence in Research : Innovative R&D Projects
Yearly calls for R&D projects since 2006 50 R&D projects submitted 16 R&D approved and financed average project budget of € 3-4 million minimum consortium = 2 companies + 2 academic labs selection by an independent international jury of experts
16 R&D projects involving 25 SMEs, 5 large companies, 40 university labs and 2 research centers
Therapeutic areas : cancer, inflammation, brain diseases
Technology domains : biomarkers, diagnostics, immunotherapy, cell therapy, drug delivery, devices & equipments
Training courses3-5 days specific training modules for people at work6-8 months training for unemployed biotech technicians
Bridges between universities and enterprisesIn-company traineeships for students working on innovation projects
Outstanding human capital
International attractiveness
BioWin is actively present on the international scene• BioWin Day (Liège – Belgium)• BioSquare (Lyon - France)• Biomedica (Liège – Belgium)• Bio US (Atlanta– USA)• Biotech China (Shangai - China)• EuroBio (Lille – France)• Medica (Dusseldörf – Germany)
With the support of
International attractiveness
• Collaborative projects (R&D, training)
• European networking
• Worldwide connections
• Networking
ERRIN
Texas A&M
Kobe-Kansai / Japan
Atlantic Biotherapies
EuroBioMed
BioWin promotes international partnerships
• Support the creation of spin-offs
• Maximize the valorization of IP originating from BioWin projects • Consolidate international collaborations
• Exchange researchers• Attract new talents• Participate into European programs (FP7, IMI, ERA-Net, …)
Key challenges for 2009 to 2015
Damien Dallemagne – Managing DirectorSylvie Ponchaut – Scientific DirectorMarianne Ghyoot – Senior R&D Project CoordinatorFrédéric Druck – Comm° & Internt’l Relations Director
Point CentreAvenue Georges Lemaître 19B-6041 GosseliesBelgium
T. +32 71/[email protected]
http://www.biowin.org
Contacts – BioWin asbl